indican has been researched along with Nephrosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, CT; Chen, JH; Chiang, CK; Huang, JW; Hung, KY; Liu, SH; Tarng, DC | 1 |
| Aoyama, I; Niwa, T; Shimokata, K | 1 |
2 other study(ies) available for indican and Nephrosclerosis
| Article | Year |
|---|---|
Early elimination of uremic toxin ameliorates AKI-to-CKD transition.
Topics: Acute Kidney Injury; Animals; Butylamines; Carbon; Drug Evaluation, Preclinical; Indican; Mice, Inbred C57BL; Nephrosclerosis; Oxides; Renal Insufficiency, Chronic; Reperfusion Injury; Senescence-Associated Secretory Phenotype; Unfolded Protein Response | 2021 |
Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats.
Topics: Adsorption; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Carbon; Cells, Cultured; Disease Progression; Drug Therapy, Combination; Fibroblasts; Fibrosis; Humans; In Situ Hybridization; Indican; Kidney; Kidney Diseases; Male; Nephrectomy; Nephrosclerosis; Osteopontin; Oxides; Rats; Rats, Sprague-Dawley; Sialoglycoproteins; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Transforming Growth Factor beta1; Uremia | 2002 |